The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Antibody therapy of cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“For example, tumour response rate was used for the approval of bevacizumab in glioblastoma and for gemtuzumab ozogamicin in relapsed acute myeloid leukaemia (AML), and progression-free survival was used for the approval of panitumumab in colorectal cance”
MethodBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Cited by
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
M1 and M2 Macrophages: Oracles of Health and Disease
Mills, C. (2012) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v32.i6.10 · Cited by 1,141
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Effect of exosomal miRNA on cancer biology and clinical applications
Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., & Yuan, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0897-7 · Cited by 800
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Dai, Q., Wilhelm, S., Ding, D., Syed, A. M., Sindhwani, S., Zhang, Y., Chen, Y. Y., MacMillan, P., & Chan, W. C. W. (2018) · ACS Nano · doi:10.1021/acsnano.8b03900 · Cited by 658
Non-genetic mechanisms of therapeutic resistance in cancer
Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 635
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S., Brons, N. H. C., Leite, S., Sauvageot, N., Sarkisjan, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09853-z · Cited by 529
Peptide–drug conjugates as effective prodrug strategies for targeted delivery
Wang, Y., Cheetham, A. G., Angacian, G., Su, H., Xie, L., & Cui, H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.015 · Cited by 514
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 485
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Targeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Trautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Chae, Y. K., Arya, A., Iams, W., Cruz, M. R., Chandra, S., Choi, J., & Giles, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0349-3 · Cited by 445
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Radiotheranostics in oncology: current challenges and emerging opportunities
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00652-y · Cited by 414
Self-citationAntibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Self-citationDual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Self-citationPhotodynamic nanomedicine in the treatment of solid tumors: Perspectives and challenges
Master, A., Livingston, M., & Sen Gupta, A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.020 · Cited by 367
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Maute, R. L., Gordon, S. R., Mayer, A. T., McCracken, M. N., Natarajan, A., Ring, N. G., Kimura, R., Tsai, J. M., Manglik, A., Kruse, A. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519623112 · Cited by 347
Recombinant pharmaceuticals from microbial cells: a 2015 update
Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0437-3 · Cited by 339
Portable, On-Demand Biomolecular Manufacturing
Pardee, K., Slomovic, S., Nguyen, P. Q., Lee, J. W., Donghia, N., Burrill, D., Ferrante, T., McSorley, F. R., Furuta, Y., Vernet, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.013 · Cited by 333
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
The Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 323
Dąbrowski, J. M., Pucelik, B., Regiel-Futyra, A., Brindell, M., Mazuryk, O., Kyzioł, A., Stochel, G., Macyk, W., & Arnaut, L. G. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.06.007 · Cited by 317
Protein Encapsulation via Polypeptide Complex Coacervation
Black, K. A., Priftis, D., Perry, S. L., Yip, J., Byun, W. Y., & Tirrell, M. (2014) · ACS Macro Letters · doi:10.1021/mz500529v · Cited by 316
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 315
Personalized protein corona on nanoparticles and its clinical implications
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Biomaterials Science · doi:10.1039/c6bm00921b · Cited by 308
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N., Hamieh, M., Hegde, M., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 303
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Jiang, T., Mo, R., Bellotti, A., Zhou, J., & Gu, Z. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201303222 · Cited by 298
Bulla, R., Tripodo, C., Rami, D., Ling, G. S., Agostinis, C., Guarnotta, C., Zorzet, S., Durigutto, P., Botto, M., & Tedesco, F. (2016) · Nature Communications · doi:10.1038/ncomms10346 · Cited by 294
The immune system in cancer metastasis: friend or foe?
Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D., & Overwijk, W. W. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0283-9 · Cited by 292
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 285
Watanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402346 · Cited by 284
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J.-P., George, B. M., Lietzenmayer, M., McKenna, K. M., Naik, T. J., McCarty, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710877114 · Cited by 283
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Biomedical Applications of DNA‐Based Hydrogels
Gačanin, J., Synatschke, C. V., & Weil, T. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906253 · Cited by 280
Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
Brahmkhatri, V. P., Prasanna, C., & Atreya, H. S. (2015) · BioMed Research International · doi:10.1155/2015/538019 · Cited by 279
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0064 · Cited by 276
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
Goeppert, B., Frauenschuh, L., Zucknick, M., Stenzinger, A., Andrulis, M., Klauschen, F., Joehrens, K., Warth, A., Renner, M., Mehrabi, A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.610 · Cited by 275
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 275
How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Yu, J., Song, Y., & Tian, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00876-4 · Cited by 269
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
Gleason, M. K., Ross, J. A., Warlick, E. D., Lund, T. C., Verneris, M. R., Wiernik, A., Spellman, S., Haagenson, M. D., Lenvik, A. J., Litzow, M. R., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533398 · Cited by 266
Boissenot, T., Bordat, A., Fattal, E., & Tsapis, N. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.026 · Cited by 264
Maleimide–thiol adducts stabilized through stretching
Huang, W., Wu, X., Gao, X., Yu, Y., Lei, H., Zhu, Z., Shi, Y., Chen, Y., Qin, M., Wang, W., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0209-2 · Cited by 258
Macroscale biomaterials strategies for local immunomodulation
Dellacherie, M. O., Seo, B. R., & Mooney, D. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0106-3 · Cited by 255
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Möckl, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00253 · Cited by 253
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0691 · Cited by 244
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Nishida-Aoki, N., Tominaga, N., Takeshita, F., Sonoda, H., Yoshioka, Y., & Ochiya, T. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.009 · Cited by 208
Abd Ellah, N. H., & Abouelmagd, S. A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1213238 · Cited by 164
Poly(Ethylene Glycol)–Polylactide Micelles for Cancer Therapy
Wang, J., Li, S., Han, Y., Guan, J., Chung, S., Wang, C., & Li, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00202 · Cited by 155
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Yin, R., & Pierce, B. G. (2024) · Protein Science · doi:10.1002/pro.4865 · Cited by 145
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Yang, D., Singh, A., Wu, H., & Kroe-Barrett, R. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.06.024 · Cited by 120
Genotoxicity and carcinogenicity risk of carbon nanotubes
Toyokuni, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.011 · Cited by 117
Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Lapidoth, G. D., Baran, D., Pszolla, G. M., Norn, C., Alon, A., Tyka, M. D., & Fleishman, S. J. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24779 · Cited by 107
Multi-angle effector function analysis of human monoclonal IgG glycovariants
Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143520 · Cited by 101
Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“Monoclonal antibodies are an established paradigm for cancer treatment (23), achieving therapeutic efficacy not only by the antigen binding variable domains, but also the fragment crystallizable (Fc) domains.”
BackgroundBeccari, S., Sierra-Torre, V., Valero, J., Pereira-Iglesias, M., García-Zaballa, M., Soria, F. N., De Las Heras-Garcia, L., Carretero-Guillen, A., Capetillo-Zarate, E., Domercq, M., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2165313 · Cited by 89
“As such, most efforts have been put into developing opsonizing antibodies to coat the tumor cells and facilitate their interaction with macrophages [52].”
BackgroundTiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
A collagen‐binding EGFR single‐chain Fv antibody fragment for the targeted cancer therapy
Liang, H., Li, X., Chen, B., Wang, B., Zhao, Y., Zhuang, Y., Shen, H., Zhang, Z., & Dai, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.029 · Cited by 54
Probst, C. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.018 · Cited by 48
Autophagy proteins regulate cell engulfment mechanisms that participate in cancer
Kim, S. E., & Overholtzer, M. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.05.004 · Cited by 35
HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer
Wang, J., Lamolinara, A., Conti, L., Giangrossi, M., Cui, L., Morelli, M. B., Amantini, C., Falconi, M., Bartolacci, C., Andreani, C., et al. (2022) · Cancers · doi:10.3390/cancers14164054 · Cited by 33
Chung, C., Wang, Q., Yang, S., Ponce, S. A., Kirsch, B. J., Zhang, H., & Betenbaugh, M. J. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26375 · Cited by 32
He, X., Long, Q., Zeng, Z., Yang, L., Tang, Y., & Feng, X. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906187 · Cited by 29
Russo, R., Rega, C., Caporale, A., Tonon, G., Scaramuzza, S., Selis, F., Ruvo, M., & Chambery, A. (2017) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7898 · Cited by 18
PPAR agonists, - could tissue targeting pave the way
Bugge, A., & Holst, D. (2017) · Biochimie · doi:10.1016/j.biochi.2016.10.017 · Cited by 14
CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges
Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz027 · Cited by 12
Sakai, T., Mashima, T., Kobayashi, N., Ogata, H., Duan, L., Fujiki, R., Hengphasatporn, K., Uda, T., Shigeta, Y., Hifumi, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43443-4 · Cited by 9
Kim, H., Ahn, T. S., Kim, C.-J., Bae, S. B., Kim, H. J., Lee, C.-S., Kim, T. H., Im, J., Lee, S. H., Son, M. W., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6203 · Cited by 8
Metadata
- Authors
- Scott, A. M., Wolchok, J. D., & Old, L. J.
- Venue
- Nature Reviews Cancer
- Published
- 2012-03-22
- Volume
- 12
- Issue
- 4
- Pages
- 278-287
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2043228552
- Cited by
- 2,160
- References
- 51
- FWCI
- 20.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.